HANSEN-TECHNOLOGIES
25.4.2024 12:01:33 CEST | Business Wire | Press release
Hansen Technologies (ASX:HSN), a leading global provider of software and services to the energy, water, and communications industries, is pleased to announce that Stockholm Exergi, a major energy provider in Sweden, is the latest to join the growing community of Hansen Trade users. Enabled by Hansen Trade, Stockholm Exergi will commence operations in a balance responsible party role and leverage the platform to process all trading operations in physical power markets, including Day-Ahead, Intraday, and Ancillary Services market trading.
Hansen Trade enables Stockholm Exergi to participate in all marketplaces with an automated trading tool, with a modern, cloud-native, and modular design. For Day-Ahead trading, the solution delivers a streamlined bidding process, detailed trade-result handling, and comprehensive safety features, making it possible to optimise all assets in the marketplace without spending time on manual processing. The fully automated Intraday Trading capability handles balance management and available capacity optimisation for all assets, round-the-clock, with highly flexible and dynamic trading strategy tools. Furthermore, the Ancillary Services capability optimises capacity in the aFRR, mFRR, and FCR markets.
Erik Forsén, Product Owner for Ancillary Services at Stockholm Exergi, commented: “To be truly effective when trading in physical marketplaces requires modern, automated trading tools. Our decision to begin operating as a balance-responsible party reinforced the need for a platform to optimise our asset fleet’s trading in multiple marketplaces. Tailored tools for bid handling and market communication convinced us that Hansen Trade was the right market solution to meet our evolving needs. Hansen also has a deep knowledge of the electricity markets and offers valuable advice on everything from strategy to operations. With Hansen Trade, we can start trading operations seamlessly and ensure that we unlock the total value potential of all our assets.”
David Castree, Chief Customer Officer at Hansen, commented: “It is clear that Stockholm Exergi are visionaries in the sector. Their transition from a conventional city-based energy provider to an active power trader, their participation in COP27, plus the announced creation – supported by the European Innovation Fund – of a carbon-capture and storage facility prove that. As such, their choice of Hansen Trade as the strategic power trading platform is all the more consequential and a genuine endorsement of Hansen’s leadership Hansen in this important space. Hansen’s power trading platform empowers several energy companies across the Nordic region, with Skelleftea Kraft, Bixia, Vantaa Energy, Tampereen Sähkölaitos, Malarenergi and Jämtkraft, to name a few. Leveraging Hansen Trade, these organisations operate with unparalleled agility in a highly dynamic market.”
Part of the Hansen Suite for Energy & Utilities, and delivered as a cloud-based SaaS solution, Hansen Trade fully meets the flexibility and scalability demands of the evolving energy trading market.
For further information about Hansen Technologies, please visit www.hansencx.com.
About Hansen
Hansen Technologies (ASX: HSN) is a leading global provider of software and services to the energy, water, and communications industries. With its award-winning software portfolio, Hansen serves customers in over 80 countries, helping them create, sell, and deliver new products and services, manage and analyse customer data, and control critical revenue management and customer support processes.
For more information, visit www.hansencx.com
Stockholm Exergi
Stockholm Exergi is Stockholm’s energy provider. Using resource-efficient solutions, Stockholm Exergi ensures that the growing Stockholm region has access to electricity, heating, cooling, and waste services. The company provides heat to more than 800,000 residents, and its 3,000-kilometre-long district heating network forms the basis for the societal benefits that Stockholm Exergi creates with its customers and partners.
For more information, visit https://www.stockholmexergi.se/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425659483/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom